Paul Matteis, an analyst from Stifel Nicolaus, reiterated the Buy rating on Rapport Therapeutics, Inc.. The associated price target was raised to $56.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Paul Matteis has given his Buy rating due to a combination of factors tied to both the advancement and breadth of Rapport Therapeutics’ pipeline. The lead asset, RAP-219, has progressed faster than expected in focal onset seizures, with a pivotal Phase 3 program now slated to begin in the second quarter of 2026 following a constructive end-of-Phase 2 meeting with the FDA. The planned Phase 3 study design broadens beyond the earlier device-enabled population to a more representative focal onset seizure cohort, which could better support registration and commercial uptake. In addition, management is preparing a long-acting injectable formulation of RAP-219, targeting first-in-human data in 2027, which could extend the product’s lifecycle and address adherence needs.
Matteis also highlights the strategic expansion of RAP-219 into primary generalized tonic-clonic seizures, a large and commercially important seizure subtype, with a Phase 3 trial expected to start in the first half of 2027, thereby increasing the program’s overall revenue potential. Beyond epilepsy, a proof-of-concept Phase 2 trial of RAP-219 in bipolar mania is underway with data expected in 2027, leveraging precedents from other anti-epileptic drugs in mood disorders. At the same time, the company has refocused resources within pain by discontinuing RAP-219 in diabetic peripheral neuropathic pain and prioritizing a preclinical α6β4 nicotinic receptor agonist program, which has shown promising analgesic and migraine activity in animal models and offers a differentiated, non-opioid approach. Collectively, the accelerated timelines, multiple late-stage indications, and a rational, data-driven portfolio reshaping support Matteis’s view that the risk/reward profile for RAPP shares is attractive at current levels, underpinning his Buy recommendation.
According to TipRanks, Matteis is a 5-star analyst with an average return of 15.2% and a 48.57% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Biogen, BioMarin Pharmaceutical, and Dyne Therapeutics.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $40.00 price target.